FEXOFENADINE HYDROCHLORIDE HIVES Drug Patent Profile
When do Fexofenadine Hydrochloride Hives patents expire, and what generic alternatives are available?
Fexofenadine Hydrochloride Hives is a drug marketed by Dr Reddys Labs Ltd, Pharmazone, Rising, Sciegen Pharms, Sun Pharm Inds, and Teva. and is included in six NDAs.
The generic ingredient in FEXOFENADINE HYDROCHLORIDE HIVES is fexofenadine hydrochloride. There is one drug master file entry for this compound. One hundred and five suppliers are listed for this compound. Additional details are available on the fexofenadine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fexofenadine Hydrochloride Hives
A generic version of FEXOFENADINE HYDROCHLORIDE HIVES was approved as fexofenadine hydrochloride by L PERRIGO CO on February 24th, 2020.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for FEXOFENADINE HYDROCHLORIDE HIVES?
- What are the global sales for FEXOFENADINE HYDROCHLORIDE HIVES?
- What is Average Wholesale Price for FEXOFENADINE HYDROCHLORIDE HIVES?
Summary for FEXOFENADINE HYDROCHLORIDE HIVES
| US Patents: | 0 |
| Applicants: | 6 |
| NDAs: | 6 |
| Finished Product Suppliers / Packagers: | 41 |
| Raw Ingredient (Bulk) Api Vendors: | 124 |
| Clinical Trials: | 87 |
| Patent Applications: | 3,307 |
| DailyMed Link: | FEXOFENADINE HYDROCHLORIDE HIVES at DailyMed |
Recent Clinical Trials for FEXOFENADINE HYDROCHLORIDE HIVES
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Karuna Therapeutics | PHASE1 |
| Abbisko Therapeutics Co, Ltd | PHASE1 |
| Tanta University | PHASE2 |
Pharmacology for FEXOFENADINE HYDROCHLORIDE HIVES
| Drug Class | Histamine-1 Receptor Antagonist |
| Mechanism of Action | Histamine H1 Receptor Antagonists |
US Patents and Regulatory Information for FEXOFENADINE HYDROCHLORIDE HIVES
Fexofenadine Hydrochloride for Hives: Market Dynamics, Patent Status, and Financial Trajectory
Fexofenadine hydrochloride is a mature, widely available second-generation antihistamine used for chronic idiopathic urticaria, commonly called hives. Its U.S. prescription exclusivity ended years ago, the product moved to over-the-counter status in 2002, and generic competition has made the active ingredient a low-margin, high-volume pharmaceutical product. Market value is concentrated in branded consumer-health products, private-label OTC sales, combination products, and international markets rather than in prescription reimbursement.
What is fexofenadine hydrochloride used for in hives?
Fexofenadine hydrochloride is an orally administered, selective peripheral histamine H1-receptor antagonist. It reduces histamine-mediated symptoms such as itching, wheals, and skin redness without the degree of central nervous system penetration associated with many first-generation antihistamines.
The FDA-approved urticaria indication covers relief of symptoms associated with chronic idiopathic urticaria in adults and pediatric patients within labeled age ranges. The product is also approved for seasonal allergic rhinitis. The drug does not remove the underlying cause of chronic spontaneous urticaria and is generally used as symptom control.
| Attribute | Fexofenadine hydrochloride |
|---|---|
| Drug class | Second-generation H1 antihistamine |
| Main hives indication | Chronic idiopathic urticaria |
| Common adult strength | 180 mg once daily |
| Other common strengths | 30 mg and 60 mg tablets |
| Dosage forms | Tablets, orally disintegrating tablets, oral suspension |
| Original brand | Allegra |
| Prescription status | Generic prescription products available |
| OTC status in the U.S. | Yes |
| Sedation profile | Generally low relative to first-generation antihistamines |
| Regulatory sponsor history | Hoechst/Aventis/Sanofi lineage for Allegra |
The FDA label warns against taking fexofenadine with certain fruit juices because absorption can be reduced. Aluminum- and magnesium-containing antacids can also reduce absorption when taken close to the antihistamine dose. These label considerations affect consumer education and brand positioning but do not create meaningful market exclusivity.[1]
How large is the fexofenadine hydrochloride hives market?
There is no separately reported global market category for fexofenadine hydrochloride used specifically for hives. Commercial sales are typically aggregated across allergic rhinitis, urticaria, and other antihistamine uses. Public companies generally report Allegra or consumer-health revenue at the brand or business-unit level rather than by indication.
The economic structure is clear:
- U.S. prescription revenue is limited because multiple generic suppliers compete on price.
- U.S. OTC revenue is more defensible because consumers recognize Allegra and retailers allocate shelf space to established brands.
- Private-label and store-brand products capture a substantial portion of unit demand.
- International revenue depends on local OTC classification, brand ownership, distributor arrangements, and pricing controls.
- Urticaria represents a clinically important use but is not separately monetized in most market reports.
Fexofenadine competes in a broad oral antihistamine market that includes cetirizine, levocetirizine, loratadine, desloratadine, bilastine, and ebastine. The largest commercial distinction is between branded consumer demand and commoditized generic supply.
What is the financial trajectory of fexofenadine hydrochloride?
The financial trajectory has followed a standard mature-drug cycle:
- Prescription launch and premium pricing.
- Expansion through allergy and urticaria indications.
- OTC conversion and mass-market distribution.
- Generic entry and prescription price erosion.
- Brand defense through advertising, packaging, formulations, and retailer relationships.
- Stable but lower-growth mature-product revenue.
Allegra benefited from the 2002 U.S. OTC switch, which expanded consumer access and reduced reliance on physician prescribing. The shift also changed the revenue model. Sales became more dependent on advertising, pharmacy and grocery distribution, seasonal allergy demand, retailer negotiations, and brand loyalty.[2]
After generic entry, the active ingredient became inexpensive to manufacture. Financial value migrated from the molecule to the consumer brand, distribution network, packaging, and supply reliability. Allegra remains commercially relevant because OTC consumers often pay a premium for a known brand even when chemically equivalent generic products are available.
Product-level public revenue should be interpreted cautiously. Sanofi historically reported Allegra within broader consumer-health disclosures, and the company did not consistently disclose revenue attributable to fexofenadine for hives. Current ownership and reporting structures can also place the brand within broader consumer-health portfolios rather than a standalone pharmaceutical segment.
When did fexofenadine lose exclusivity?
Fexofenadine lost meaningful U.S. market exclusivity in the early 2000s. The original prescription product was launched in the 1990s, and the FDA approved the OTC switch in 2002. Generic prescription versions subsequently entered the market after the relevant regulatory and patent barriers expired.
The original compound and early product patents are long expired. No commercially significant U.S. compound patent protects fexofenadine hydrochloride today. The market is therefore governed by generic competition, manufacturing economics, regulatory compliance, and brand execution rather than by core molecule exclusivity.
Exclusivity timeline
| Period | Commercial event | Market effect |
|---|---|---|
| 1990s | Prescription Allegra launch | Premium branded pricing |
| 1996 | FDA approval of Allegra tablets for allergic rhinitis and urticaria-related use | Expanded labeled demand |
| 2002 | FDA approval of OTC switch | Broader consumer access and mass-market promotion |
| Early 2000s | Generic fexofenadine availability | Prescription price and share erosion |
| 2010s | Expansion of private-label OTC products | Increased retail price competition |
| 2020s | Mature antihistamine market | Stable demand, limited molecule-level growth |
The exact generic-entry date varied by strength, dosage form, manufacturer, and litigation history. Commercially, the important point is that the drug no longer has meaningful U.S. prescription exclusivity.
What is the Orange Book status of fexofenadine hydrochloride?
The FDA Orange Book is relevant mainly to approved prescription products and listed patents. Fexofenadine hydrochloride does not have a current patent estate comparable to a recently launched branded prescription medicine. Original compound and primary product protection have expired, and generic approvals have been available for years.
An Orange Book review should distinguish among:
- Historic Allegra listings.
- Current prescription products.
- OTC versions, which are not managed in the same way as prescription products.
- Combination products and suspension formulations.
- Patents that expired before current generic competition.
- Any later formulation or packaging rights, which would not restore molecule-level exclusivity.
The practical legal position is that an ANDA filer does not face a material current patent barrier from the original fexofenadine molecule. Any remaining patent issue would more likely concern a specific formulation, manufacturing process, combination, or device rather than ordinary immediate-release fexofenadine tablets.
Are there Paragraph IV challenges involving fexofenadine?
Historical Paragraph IV activity may have accompanied generic entry, particularly for branded prescription products and specific formulations. Current commercial risk from Paragraph IV litigation is low because the central patents covering fexofenadine have expired and the product has been generic for many years.
Paragraph IV certifications are significant when a generic applicant challenges an unexpired Orange Book patent. They are not a continuing source of exclusivity for ordinary fexofenadine hydrochloride tablets today. Any new Paragraph IV dispute would likely involve a newly listed formulation patent, combination product, or delivery technology.
The absence of an active core patent also reduces the expected value of patent litigation. Generic applicants have little reason to delay entry when multiple suppliers already participate in the market.
What formulations are protected by fexofenadine patents?
The principal commercial forms are immediate-release tablets, orally disintegrating tablets, and oral suspension. Original formulation patents covering these products have expired or no longer create meaningful market exclusivity.
Potentially differentiated formulation areas include:
- Orally disintegrating tablets.
- Pediatric suspensions.
- Fixed-dose combinations with decongestants such as pseudoephedrine.
- Modified-release or controlled-release presentations.
- Taste-masked pediatric products.
- Packaging designed for OTC compliance.
- Manufacturing processes that improve impurity control or yield.
These features can support product differentiation, but they rarely create durable economic barriers. A formulation patent must be enforceable, commercially relevant, and difficult to design around. In a low-cost OTC antihistamine market, the return on formulation investment is often limited unless the product commands a strong retail premium.
Which companies compete with fexofenadine hydrochloride?
Competition operates at both the molecule and therapeutic-class levels.
| Competitor | Active ingredient | Commercial position |
|---|---|---|
| Allegra | Fexofenadine | Leading legacy brand |
| Zyrtec | Cetirizine | Strong OTC brand and generic presence |
| Claritin | Loratadine | Major OTC brand |
| Xyzal | Levocetirizine | Branded and generic antihistamine |
| Clarinex | Desloratadine | Smaller branded prescription/OTC footprint depending on market |
| Bilastine products | Bilastine | International prescription or OTC competitor |
| Ebastine products | Ebastine | International competitor |
| Store brands | Various | Low-price private-label alternatives |
For hives, clinicians often begin with a second-generation H1 antihistamine. International urticaria guidelines permit dose escalation of second-generation antihistamines in selected patients who do not respond to standard doses, although such use can be jurisdiction-dependent and may be outside the U.S. product label.[3]
Severe or refractory chronic spontaneous urticaria creates competition from biologic therapy, especially omalizumab, and from newer targeted agents such as dupilumab in applicable indications. These products do not replace routine antihistamine use in all patients, but they capture higher-value treatment segments.
How does fexofenadine compare with cetirizine and loratadine?
Fexofenadine competes effectively on low sedation and long-standing consumer familiarity. Cetirizine can be perceived as more potent by some consumers but is more associated with drowsiness. Loratadine competes on established brand recognition and broad private-label availability.
| Factor | Fexofenadine | Cetirizine | Loratadine |
|---|---|---|---|
| Sedation perception | Low | Higher in some users | Generally low |
| Once-daily options | Yes | Yes | Yes |
| U.S. OTC presence | Strong | Strong | Strong |
| Generic availability | Extensive | Extensive | Extensive |
| Brand differentiation | Allegra | Zyrtec | Claritin |
| Pricing pressure | High | High | High |
| Hives use | Established | Established | Established |
No single product has a durable molecule-level advantage in routine hives treatment. Commercial performance depends on price, perceived onset, sedation expectations, physician preference, retailer placement, and advertising.
What patent litigation affects fexofenadine hydrochloride?
Current high-value patent litigation risk is limited. The principal litigation period occurred around generic entry and the transition from prescription to OTC commercialization. The key legal disputes for a mature product were likely to involve patent validity, infringement, regulatory exclusivity, and formulation differences rather than the clinical use of fexofenadine for hives itself.
A new entrant would face more practical risk from:
- FDA manufacturing deficiencies.
- Product recalls.
- Supply interruptions.
- Active pharmaceutical ingredient qualification.
- OTC monograph or labeling compliance.
- Retailer contracting.
- Trademark and trade-dress claims.
- Combination-product formulation rights.
Trademark protection for Allegra remains commercially relevant even though patent protection has expired. Trademark law can prevent confusingly similar branding, but it does not prevent generic manufacturers from selling fexofenadine hydrochloride under their own names.
What generic launch scenarios exist for fexofenadine?
The ordinary generic launch scenario is already established. Multiple suppliers can manufacture and market immediate-release fexofenadine products, subject to FDA approval and applicable OTC or prescription requirements.
Potential future launch opportunities are concentrated in narrower niches:
Pediatric formulations
Oral suspensions and taste-masked products can command higher margins than basic tablets if they solve dosing or palatability problems. The market remains price-sensitive because parents and caregivers can substitute among antihistamines.
Combination products
Fexofenadine-pseudoephedrine combinations offer congestion relief but face regulatory, supply, and consumer-use constraints associated with pseudoephedrine. These products may have higher retail prices but also greater operational complexity.
International markets
In countries where fexofenadine remains prescription-only or where local brands are less established, a manufacturer may obtain better pricing. Geographic opportunity depends on registration requirements, local patent status, reimbursement, and distributor access.
Private-label retail
Retailers can use store-brand fexofenadine to compete with Allegra on price. This is a volume opportunity with thin gross margins and strong requirements for reliable supply.
What manufacturing and intellectual-property barriers remain?
Fexofenadine manufacturing does not present the same barrier as a complex biologic, sterile injectable, or highly engineered delivery system. The active ingredient is a small molecule with established commercial manufacturing routes.
Remaining barriers include:
- Validated API supply.
- Impurity and residual-solvent control.
- Stable tablet and suspension manufacturing.
- Bioequivalence for prescription products.
- OTC labeling compliance.
- Packaging and child-resistant closure requirements.
- Seasonal demand forecasting.
- Retailer service levels.
- Global regulatory registrations.
The strongest commercial barrier is often distribution rather than intellectual property. Allegra benefits from consumer recognition and pharmacy shelf presence, while generic suppliers compete through procurement scale and low-cost manufacturing.
What is the regulatory status of fexofenadine for hives?
Fexofenadine hydrochloride is FDA approved for chronic idiopathic urticaria and allergic rhinitis in specified patient populations and dosage forms. U.S. OTC products are marketed under the FDA’s OTC framework, while prescription generics may remain available for certain strengths or presentations.
FDA regulatory value is mature rather than innovative. There is no pending new-drug exclusivity comparable to a recently approved therapy. Regulatory risk centers on manufacturing quality, labeling accuracy, adverse-event reporting, and product consistency.
Fexofenadine is not a biologic, so biosimilar risk does not apply. Its competitive threat comes from generic small-molecule products and other antihistamines, not biosimilar substitution.
How strong is the fexofenadine patent estate?
The patent estate is weak from a current exclusivity perspective and historically important from a product-development perspective.
| Patent-estate category | Current strength |
|---|---|
| Core compound patents | Expired |
| Original tablet patents | Expired or commercially obsolete |
| U.S. prescription exclusivity | Expired |
| OTC brand protection | Trademark-based |
| New formulation patents | Potentially relevant only to specific products |
| Manufacturing patents | Limited commercial blocking power unless narrowly essential |
| Method-of-use patents for hives | Low practical value for ordinary use |
A new entrant should assume that the active ingredient is open to competition. Defensibility would need to come from formulation, dosage convenience, combination therapy, pediatric delivery, supply reliability, or consumer branding.
What is the commercial outlook for fexofenadine hydrochloride?
The outlook is stable but low growth. Demand should remain supported by seasonal allergies, chronic urticaria prevalence, consumer preference for less-sedating antihistamines, and broad OTC access. Revenue growth is constrained by generic substitution, retailer pricing, mature category penetration, and competition from cetirizine and loratadine.
The most attractive opportunities are incremental:
- Premium pediatric products.
- Combination products.
- International registrations.
- Retailer private-label contracts.
- Brand extensions with differentiated packaging or dosing.
- Reliable low-cost supply during seasonal demand peaks.
The molecule is unlikely to generate pharmaceutical-style monopoly returns. Its value lies in recurring consumer demand, manufacturing scale, and brand or channel execution.
Key Takeaways
- Fexofenadine hydrochloride is an established second-generation antihistamine approved for chronic idiopathic urticaria and allergic rhinitis.
- Allegra moved from prescription to OTC status in the U.S. in 2002.
- Core compound and primary product patents have expired.
- Generic competition has eliminated meaningful molecule-level exclusivity.
- The market is driven by OTC branding, private-label volume, retail distribution, and low-cost manufacturing.
- Fexofenadine competes directly with cetirizine, loratadine, levocetirizine, and other second-generation antihistamines.
- Biosimilar risk does not apply because fexofenadine is a small-molecule drug.
- Current litigation risk is more likely to involve formulation, trademark, manufacturing, or labeling issues than core patent infringement.
- Product-specific revenue for the hives indication is not separately disclosed by major manufacturers.
- Commercial growth is likely to remain limited, with niche opportunities in pediatric delivery, combination products, international markets, and private-label supply.
FAQs
Is fexofenadine hydrochloride still profitable after generic entry?
Yes, but profitability depends on scale, supply efficiency, brand strength, and distribution. Generic tablet margins are usually lower than branded OTC margins.
Can a company patent a new fexofenadine hives treatment?
A new formulation, delivery system, combination, or manufacturing process may be patentable if it satisfies novelty, inventive-step, and patentability requirements. The fexofenadine molecule itself is no longer a viable source of new composition-of-matter exclusivity.
Does Allegra have exclusivity for chronic hives?
No. Allegra does not have current molecule-level exclusivity for chronic hives. Generic fexofenadine products can compete, subject to product-specific regulatory requirements.
Is fexofenadine stronger than loratadine for hives?
Neither drug has a universal clinical advantage for every patient. Both are established second-generation antihistamines, and response varies by patient, dose, tolerability, and disease severity.
Can chronic hives support premium pricing for fexofenadine?
Usually not for ordinary tablets because consumers and pharmacies can substitute generic antihistamines. Premium pricing is more feasible for branded OTC products, pediatric formulations, combination products, or differentiated delivery systems.
References
- U.S. Food and Drug Administration. (2023). Allegra fexofenadine hydrochloride prescribing information. FDA.
- U.S. Food and Drug Administration. (2002). FDA approves over-the-counter Allegra for allergy relief. FDA.
- Zuberbier, T., Abdul Latiff, A. H., Abuzakouk, M., Aquilina, S., Asero, R., Baker, D., Ballmer-Weber, B., Bangert, C., Ben-Shoshan, M., Bindslev-Jensen, C., et al. (2022). The international guideline for the definition, classification, diagnosis, and management of urticaria. Allergy, 77(3), 734-766.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. FDA.
More… ↓
